Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321),...
Q4 2026
Sep 2, 2026
Q2 2026
Jan 30, 2026
FY 2025
Sep 3, 2025
Q4 2025
Q2 2025
Feb 27, 2025
